KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (NYSE:KKR) announced on Wednesday the acquisition of a majority stake in biopharma royalty acquisition company, HealthCare Royalty Partners. The acquisition marks KKR's expansion ...

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

KKR executives said strong momentum in their business gave them confidence on Thursday of beating earnings targets for 2026, ...

Investment giant KKR reported a 9% rise in adjusted net income for the second quarter on Thursday, bolstered by an increase ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

Q2 2025 Earnings Call Transcript July 31, 2025 KKR & Co. Inc. beats earnings expectations. Reported EPS is $1.18, ...

Detailed price information for KKR & Company LP (KKR-N) from The Globe and Mail including charting and trades.

The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker Sri Rao. The credit-card company reported increases in profit and sales in the ...

The royalty aggregator’s proposed deals for HilleVax and Lava add to a pattern of “zombie” biotech buyouts this year as the ...

Shares in Microsoft and Meta soared to new highs on Thursday after the tech giants committed to invest billions more on ...